This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (26)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Neuroleptic malignant syndrome (NMS) is a serious and potentially lethal complication that may infrequently occur in patients treated with antipsychotic drugs. The main clinical features include rigidity and other extrapyramidal signs, autonomic disturbances such as hyperthermia, tachycardia, and hypertension, altered level of consciousness, various signs of acute encephalopathy, and elevation of serum creatine kinase enzyme levels.¹ Neuroleptic malignant syndrome has been associated with virtually all conventional neuroleptic agents, but is thought to be exceptional with the use of atypical neuroleptics, such as clozapine, that produce less extrapyramidal symptoms and tardive dyskinesia. Olanzapine is a novel, atypical neuroleptic that recently has become available worldwide and has the advantage over clozapine of inducing no agranulocytosis. Recent large studies² have confirmed its atypical properties, and no NMS has been reported with its use. We describe a patient with a previous episode of NMS caused by conventional neuroleptics, who developed a typical but moderately . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?